logo
Teaching blood cells how to 'switch off' arthritis

Teaching blood cells how to 'switch off' arthritis

Yahoo24-03-2025
Patients are taking part in a trial that scientists hope could ultimately lead to a cure for rheumatoid arthritis.
The AuToDeCRA-2 study seeks to prove it is possible to train white blood cell commanders - dubbed the "generals" of the immune system - to order other "soldier" cells to stop attacking healthy tissues.
Prof John Isaacs, who has worked on the condition for 35 years and is leading the research, believes this could make it possible to "switch off" rheumatoid arthritis.
Trial participant Carol Robson, from Jarrow in South Tyneside, says the worst part of living with the disease is the pain, but if the research helps ease suffering "that would be wonderful".
The study, funded by the charity Versus Arthritis and the European Commission, is being run by Newcastle University and Newcastle Hospitals.
"It's pioneering," Prof Isaacs claims. "There are only one or two other groups around the world doing similar work."
In this latest research, now in its second phase, certain cells are isolated from a patient's blood.
Prof Isaacs explained there are different types of cells that come together, rather like an army of soldiers, to attack an infection or disease.
These take instructions from the white blood cells known as dendritic cells, which he refers to as the "generals" of the immune system.
When these generals sense danger they become excited and send out the attack signal, but when there is no danger detected they remain calm and instruct the army to ignore healthy tissues.
When this goes wrong it causes diseases like rheumatoid arthritis.
Over the course of a week the patient's white blood cells are grown in the lab and trained to resemble the "calm" generals so that, when given back to the patient, they command the soldiers to stop attacking the patient's joints.
"In time, this treatment could provide significant benefits to people living with rheumatoid arthritis by 'switching off' the disease," Prof Isaacs explains.
Among the estimated 450,000 people in England who live with the condition is 70-year-old former nurse Ms Robson. She wakes up every morning to pain.
Before she was diagnosed she would put her hands in packets of frozen peas in an effort to find some relief.
She now takes immunosuppressants, which she says help a bit, but since being injected with the retrained white blood cells she believes she is in less pain.
"Is this just me hoping it is? But realistically I do think it is better," she says.
"If this trial works to switch off rheumatoid arthritis that would be wonderful.
"It's a privilege to be part of something that is actually quite a leap forward - if they get it right."
The outcome of the Newcastle work is being widely monitored as it could have huge implications for the 18 million rheumatoid arthritis patients worldwide.
Prof Isaacs said, if its successful, the research could also have implications for other autoimmune diseases such as diabetes or multiple sclerosis.
"It's an area of research that we describe as re-education of the immune system.
The first two trials are small - in total about 32 patients have been involved - and more research is needed, but if it shows signs of success another, larger trial will follow.
Even if all goes to plan and the treatment is shown to re-educate the immune system, it may still be another five to 10 years before patients are able to access it.
But Prof Isaacs, who has dedicated his career to the condition, said it would make him and his team immensely proud to have developed the treatment.
Follow BBC North East on X, Facebook, Nextdoor and Instagram.
AI researchers work on detecting arthritis earlier
Newcastle Hospitals
Professor John Isaacs
Versus Arthritis
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SpaceX Dragon delivers Crew-11 to International Space Station
SpaceX Dragon delivers Crew-11 to International Space Station

UPI

time5 hours ago

  • UPI

SpaceX Dragon delivers Crew-11 to International Space Station

1 of 3 | The four Crew-11 members are greeted by the seven-member Expedition 73 crew aboard the International Space Station. Photo by NASA Aug. 2 (UPI) -- The four Crew-11 crew members joined seven other astronauts in the International Space Station early Saturday morning following a 15-hour journey from Kennedy Space Center in Florida. NASA astronauts Zena Cardman and Mike Fincke, Japan Aerospace Exploration Agency astronaut Kimiya Yui, and Roscosmos cosmonaut Oleg Platonov, entered the ISS at 3:46 a.m. EDT, NASA said. At 2:27 a.m., the SpaceX Dragon spacecraft docked at the ISS's Harmony module, and then the crew conducted standard leak checks and pressurization between the two spacecraft. The docking occurred as the two spacecraft were 264 miles above the South Pacific Ocean. "Endeavour, welcome to the International Space Station," NASA astronaut Jonny Kim said from inside the ISS. "Zena, Mike, Kimi and Oleg, we have cold drinks, hot food and hugs waiting. See you soon." The six ISS crew members already on board are JAXA's Takuya Onishi, commander of the current Expedition 73 mission; Anne McClain and Nichole Ayers of NASA; and cosmonauts Kirill Peskov, Sergey Ryzhikov and Alexey Zubritsky. Crew-10 members Ayers, McClain, Onishi and Peskov, who have been on ISS since mid-March, will head home in a few days. "Hello space station, Crew 11 is here!" Fincke, the Endeavour pilot, replied. "And we are super excited to join Expedition 73. We will do our best to also be good stewards of our beautiful ISS during our stay. The ISS has been inhabited and crewed for almost 25 years. We look forward to celebrating with you." The docking was exactly five years after the splashdown of Space X's first crewed mission, the Demo-2 test flight, aboard the Endeavour. The spacecraft has been involved in six missions and is the most-flown of the Crew Dragon capsules. On Friday, the Falcon 9 rocket lifted off at 11:43 a.m. from Kennedy Space Center in Florida after being scrubbed on Thursday because of inclement weather. It is the first spaceflight for Cardman and Platonov, the second for Yui and the fourth for Fincke. Cardman and Plantonov were supposed to fly last year as part of Crew 9 on Sept. 8, 2024, but that Dragon capsule was used at the ISS by Boeing Starliner pilots Butch Wilmore and Suni Williams. Their stay lasted nine months instead of one week because of problems with Starliner. "This has been the absolute journey of a lifetime," Cardman said. "We are so incredibly grateful to be here. Thank you so much for this warm welcome. It was such an unbelievably beautiful sight to see the space station come into our view for the first time, especially with these wonderful crewmates." SpaceX has flown 11 operational astronaut missions to the ISS. Also, SpaceX has eight other crewed missions -- Demo 2, four private efforts by Axiom Space and three free-flying ones to orbit.

NASA Crew-11 astronauts to launch on SpaceX rocket from Kennedy Space Center Thursday
NASA Crew-11 astronauts to launch on SpaceX rocket from Kennedy Space Center Thursday

Yahoo

time2 days ago

  • Yahoo

NASA Crew-11 astronauts to launch on SpaceX rocket from Kennedy Space Center Thursday

NASA and SpaceX are set to launch the next crew to the International Space Station this week — and the launch will bring a sonic boom. Launch of Crew-11 is currently set for 12:09 p.m. July 31 from NASA's Kennedy Space Center Pad 39A. The crew of four will travel in a SpaceX Dragon spacecraft atop a SpaceX Falcon 9 rocket. Onboard will be NASA astronauts Zena Cardman and Mike Fincke, JAXA (Japan Aerospace Exploration Agency) astronaut Kimiya Yui, and Roscosmos cosmonaut Oleg Platonov. If the launch is on time, the four will arrive at the space station no earlier than 3 a.m. August 2. While it will be the first spaceflight for Cardman and Platonov, the other two crew members bring experience. It will be former shuttle astronaut Fincke's fourth spaceflight and the second for Yui. The road to launch has not been without snags for SpaceX. During a July 28 prelaunch test fire of the Falcon 9 rocket, the process was aborted by the computer with only 57 seconds on the clock. SpaceX attributed the failed test fire to 'an error within transporter erector's cradle arm position indication'. SpaceX stated there were no issues with the rocket and Dragon spacecraft, and successfully completed the test fire of the rocket on July 29 − ahead of the July 31 launch. SpaceX Dragon launching NASA's Crew-11 Crew-11 marks the 11th crew rotation and 12th launch overall of NASA astronauts in partnership with SpaceX as part of the Commercial Crew Program. The first was Demo-2 in 2020, which certified the SpaceX Dragon spacecraft to ferry NASA astronauts to the ISS. The SpaceX Dragon spacecraft launching Crew-11 is well traveled. It is the same Dragon which launched Demo-2 in 2020 − Crew Dragon Endeavour. It also launched Crew-2 in 2021, Axiom Space Mission 1 in 2022, Crew-6 in 2023, and Crew-8 in 2024. NASA recently worked with SpaceX to certify Dragon to fly beyond the previously certified five flights per capsule. Eventually, NASA hopes to certify Dragon up to 15 flights per capsule. When is the next Florida launch? Is there a launch today? Upcoming SpaceX, NASA, ULA rocket launch schedule at Cape Canaveral SpaceX launch from Kennedy Space Center to bring sonic boom How to see the Falcon 9 booster land: After the SpaceX rocket launch, here's how to see the booster land at Cape Canaveral SFS Being a flight to the ISS, SpaceX will be landing the booster of the Falcon 9 rocket back at the Cape Canaveral Landing Zone. Those in the surrounding areas can expect a loud sonic boom to follow the launch, as the booster announces its return. This is due to the booster coming in faster than the speed of sound. Spectators will see the booster land before hearing the thunderous noise. The FLORIDA TODAY Space Team will provide live updates beginning two-hours prior to launch at Brooke Edwards is a Space Reporter for Florida Today. Contact her at bedwards@ or on X: @brookeofstars. This article originally appeared on Florida Today: NASA Crew-11 astronauts to launch on SpaceX rocket Thursday from KSC Solve the daily Crossword

Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data
Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data

Yahoo

time2 days ago

  • Yahoo

Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data

We recently compiled a list of Crinetics Pharmaceuticals, Inc. stands fifth on our list. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands fifth on our list among the best future growth stocks to buy now. It is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies for rare endocrine diseases and tumors. Its lead candidate, PALSONIFY (paltusotine), is an investigational once-daily oral somatostatin receptor type 2 (SST2) agonist being developed for acromegaly. At the July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly. The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY the first oral treatment approved for acromegaly. This would represent a significant shift in disease management and convenience for patients. A scientist in a laboratory looking into a microscope, researching advances in biopharmaceuticals for central nervous system disorders. Beyond PALSONIFY, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is advancing other pipeline programs, including Atumelnant, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as several early-stage endocrine disorder therapies. The corporation also expanded its workforce in July 2025, granting equity awards to 46 new employees to support future growth. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store